Endpoints' #ASCO26 coverage continues Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 1 June, 2026

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

news Lilly enters GLP-2 space in deal with Korea's Hanmi, also forges discovery pact with China's Haisco •  Post-Hoc: The world's biggest drugmaker gets more secretive Oculis’ eye drops for diabetic macular edema flunk Phase 3 test J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain Yes, Revolution Medicines' pancreatic cancer data are that good Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

Jun 11 11:00 am ET Data-driven manufacturing: Enhancing process robustness across sites sponsored by Samsung Biologics

Senior Director, Licensing Officer Bayer Cambridge, MA, USA Director, Government Pricing Sandoz Princeton, NJ, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

MORE FROM #ASCO26 Personalized cancer vaccines may help some brain cancer patients live longer Grail’s cancer blood test still isn’t ready for widespread use, experts say Bristol Myers details Phase 3 trial win for Pomalyst successor

in case you missed it 1. FDA's next fee deal, stacked with US incentives, is under White House review 2. Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections 3. Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs 4. Peer Review David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow 5. Agios ends development of tebapivat in low-risk MDS following subpar results 6. Science sleuths uncover more than 100 suspicious images in Thermo Fisher antibody catalogue 7. New protein-folding AI predicts the structures of 1 billion proteins Scientific American